GM01861
LCL from B-Lymphocyte
Description:
NEUROFIBROMATOSIS, TYPE I; NF1
NEUROFIBROMIN 1; NF1
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases Hereditary Cancers |
Class |
Other Disorders of Known Biochemistry |
Biopsy Source
|
Peripheral vein
|
Cell Type
|
B-Lymphocyte
|
Tissue Type
|
Blood
|
Transformant
|
Epstein-Barr Virus
|
Sample Source
|
LCL from B-Lymphocyte
|
Race
|
White
|
Family Member
|
1
|
Relation to Proband
|
proband
|
Confirmation
|
Clinical summary/Case history
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase, Glucose-6-Phosphate Dehydrogenase, and Lactate Dehydrogenase Isoenzyme Electrophoresis |
|
Gene |
NF1 |
Chromosomal Location |
17q11.2 |
Allelic Variant 1 |
; NEUROFIBROMATOSIS, TYPE I; NF1 |
Identified Mutation |
c.1183insT (p.395X) |
Remarks |
cafe au lait spots and neurofibromas; HLA type A3,A2,B27,Bw22(Bw40); Sanger sequencing identified a mutation: c.1183insT (het) (NM_001042492.2; Exon10). This mutation leads to a frameshift causing a premature stop codon downstream (p.395X); see also GM01858B and GM01859 Fibroblast;
|
Vincent A, Heitz D, Petit C, Kretz C, Oberle I, Mandel JL, Abnormal pattern detected in fragile-X patients by pulsed-field gel electrophoresis. Nature349:624-6 1991 |
PubMed ID: 1672039 |
Split Ratio |
1:3 |
Temperature |
37 C |
Percent CO2 |
5% |
Medium |
Roswell Park Memorial Institute Medium 1640 with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not Inactivated |
Substrate |
None specified |
Subcultivation Method |
dilution - add fresh medium |
Supplement |
- |
|
|